Krystal Biotech, Inc. (KRYS): Price and Financial Metrics


Krystal Biotech, Inc. (KRYS)

Today's Latest Price: $73.00 USD

1.82 (2.56%)

Updated Jan 25 4:00pm

Add KRYS to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

KRYS Stock Price Chart Interactive Chart >

Price chart for KRYS

KRYS Price/Volume Stats

Current price $73.00 52-week high $73.30
Prev. close $71.18 52-week low $33.08
Day low $69.73 Volume 82,700
Day high $73.29 Avg. volume 123,187
50-day MA $57.01 Dividend yield N/A
200-day MA $48.85 Market Cap 1.44B

Krystal Biotech, Inc. (KRYS) Company Bio

Krystal Biotech Inc. develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The company’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. The company was founded in 2015 and is based in Pittsburgh, Pennsylvania.

Most Popular Stories View All

• Is General Motors the Next Tesla?

• How to Outperform the Stock Market in 2021

• 2 Chinese Stocks Rated Strong Buy: EHang and Daqo

• 3 Lesser-Known Cloud Stocks to Add to Your Portfolio

• Is Virgin Galactic a Buy After a New Space Stock ETF was announced?

View All Top Stories

KRYS Latest News Stream

Event/Time News Detail
Loading, please wait...
View All KRYS News

KRYS Latest Social Stream

Loading social stream, please wait...

View Full KRYS Social Stream

Latest KRYS News From Around the Web

Below are the latest news stories about Krystal Biotech Inc that investors may wish to consider to help them evaluate KRYS as an investment opportunity.

The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech I...

Benzinga | January 22, 2021

H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc By Investing.com

H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc

Investing.com | January 8, 2021

Krystal Biotech lays out catalysts for 2021

Today, in a regulatory filing, Krystal Biotech ([[KRYS]] +1.6%) disclosed the key milestones expected for the company’s pipeline in the year ahead. The timeline includes four data readouts, one trial initiation, and a possible IND filing.With topline data expected in 2H 2021, the pivotal Phase 3 (GEM-3) trial stands out from the...

Seeking Alpha | January 7, 2021

Krystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD, FRCS, FMedSci, and Jing L. Marantz, MD, PhD, MBA to its board of directors. “We are pleased to welcome Drs. Mason and Marantz to our board of directors,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. “They bring significant gene therapy translational and rare diseas

Business Wire | January 4, 2021

Krystal Biotech to Present at the Evercore ISI HealthCONx Conference

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief executive officer will be participating in a fireside chat at the Evercore ISI 3rd Annual HealthCONx virtual conference taking place December 1-3, 2020. Details for the webcast are as follows: Evercore ISI 3rd Annual HealthCONx virtual conference Presentation Date: Tuesday, December 1, 2020 Presentation Ti

Business Wire | November 24, 2020

Read More 'KRYS' Stories Here

KRYS Price Returns

1-mo N/A
3-mo 59.25%
6-mo 70.92%
1-year 26.39%
3-year 626.37%
5-year N/A
YTD 21.67%
2020 8.34%
2019 166.51%
2018 97.53%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7772 seconds.